Klaus Kutz
Chief Tech/Sci/R&D Officer at PROPANC BIOPHARMA, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Nathanielsz | M | 50 | 17 years | |
| Julian Kenyon | M | 77 | 17 years | |
| Rudolf Fahrig | M | 83 |
RESprotect GmbH
 RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | 24 years |
| Torsten Fahrig | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Josef Zelinger | M | 74 | 4 years | |
| Johannes Oldenburg | M | - |
University of Bonn
| - |
| Bernhard Matter | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Siegfried Knasmüller | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Robert Schiestl | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Clemens Unger | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Klaus Engel | M | 67 |
University of Bonn
| - |
| Frank Perabo | M | 59 |
University of Bonn
| - |
| Katrin Vernau | M | - |
University of Bonn
| - |
| Lothar Alexander Harings | M | 64 |
University of Bonn
| - |
| Robert Lammens | M | - |
University of Bonn
| - |
| Andreas Koch | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Jörg-Christian Heinrich | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
| Karsten Buse | M | - |
University of Bonn
| - |
| Herbert Müsch | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 16 | 84.21% |
| Australia | 3 | 15.79% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Klaus Kutz
- Personal Network